Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: Model to predict HCV cirrhosis after liver transplantation

Transplantation

Volumn 84, Issue 1, 2007, Pages 56-63

  Iacob, Speranta ^a,b   Cicinnati, Vito R ^a   Hilgard, Philip ^a   Iacob, Razvan A ^b   Gheorghe, Liana S ^b   Popescu, Irinel ^b   Frilling, Andrea ^a   Malago, Massimo ^a   Gerken, Guido ^a   Broelsch, Christoph E ^a   Beckebaum, Susanne ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Hepatitis C virus; Mortality; Outcome; Recurrence; Retransplantation

Indexed keywords

AZATHIOPRINE; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; UNIVARIATE ANALYSIS;

COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HLA-DR3 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, THEORETICAL; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREDNISONE; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34447641669     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000267916.36343.ca     Document Type: Article

References (58)

1. Zimmerman MA, Trotter JF. Living donor liver transplantation in patients with hepatitis C. Liver Transpl 2003; 9: S52.
2. Everhart JE, Wei Y, Eng H, et al. Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 1999; 29: 1220.
3. Berenguer M. Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transpl 2003; 9: S44.
4. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42: 448.
5. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29: 250.
6. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852.
7. Saab S, Niho H, Comulada S, et al. Mortality predictors in liver transplant recipients with recurrent hepatitis C cirrhosis. Liver International 2005; 25: 940.
8. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823.
9. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: Results of the NIDDK Liver transplantation database. Liver Transpl 2004; 10: 1120.
10. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907.
11. Broelsch CE, Frilling A, Malago M. Should we expand the criteria for liver transplantation for hepatocellular carcinoma - Yes, of course! J Hepatol 2005; 43: 569.
12. Shen L, Li JQ, Zeng MD, et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006; 12: 1292.
13. Runyon BA. Ascites and spontaneous bacterial peritonitis. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. Philadelphia: WB Saunders, 2002: 1517.
14. Fitz JG. Hepatic encephalopathy, hepatopulmonary syndromes, hepatorenal syndrome, coagulopathy and endocrine complications of liver disease. In: Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger & Fordtran's Gastrointestinal and Liver Disease. Pathophysiology/Diagnosis/Management. Philadelphia: WB Saunders, 2002: 1543.
15. Batts KP, Ludwig J. Chronic hepatitis an update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409.
16. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Available at: www.ustransplant.org. Accessed 10 November 2005.
17. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003; 38: 34.
18. Powner D. Factors during donor care that may affect liver transplantation outcome. Progress Transplant 2004; 14: 241.
19. Sun CK, Zhang XY, Zimmermann A, Davis G, Wheatley AM. Effect of ischemia-reperfusion injury on the microcirculation of the steatotic liver of the Zucker rat. Transplantation 2001; 72: 1625.
20. Selzner N, Selzner M, Jochum W, et al. Mouse livers with macrosteatosis are more susceptible to normothermic ischemic injury than those with microsteatosis. J Hepatol 2006; 44: 694.
21. Pascher A, Neuhaus P. Bile duct complications after liver transplantation. Transplant Int 2005; 18: 627.
22. Garcia-Retortillo M, Forns X, Llovet JM, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40: 699.
23. Ben-Ari Z, Pappo O, Mor E. Intrahepatic cholestasis after liver transplantation. Liver Transpl 2003; 9: 1005.
24. Svegliati-Baroni G, Ridolfi F, Hannivoort R, et al. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 2005; 128: 1042.
25. Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: A prospective, randomized trial. Liver Transpl 2004; 10: 1258.
26. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63.
27. Hilgard P, Kahraman A, Lehmann N, et al. Cyclosporine versus tacrolimus as immunosuppresion after liver transplantation in patients with chronic hepatitis C: Effects on virus replication and recurrent hepatitis. World J Gastroenterol 2006; 12: 697.
28. Brillanti S, Vivarelli M, De Ruvo N, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002; 8: 884.
29. Berenguer M. Outcome of posttransplantation hepatitis C virus disease - is it the host, the virus, or how we modify the host and/or the virus? Liver Transpl 2002; 8: 889.
30. McCaughan GW, Zekry A. Impact of immunosuppression on immunopathogenesis of liver damage in hepatitis C virus-infected recipients following liver transplantation. Liver Transpl 2003; 9: S21.
31. Berenguer M, Aguilera V, Prieto M, et al. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression. J Hepatol 2006; 44: 717.
32. Bahra M, Neumann UP, Jacob D, et al. Repeated steroid pulse therapies in HCV-positive liver recipients: Significant risk factor for HCV-related graft loss. Transplant Proc 2005; 37: 1700.
33. Sheiner PA, Schwartz ME, Mor E, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21: 30.
34. Gane EJ, Naoumov NV, Qian KP, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110: 167.
35. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125.
36. Hunt J, Gordon FD, Lewis WD, et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: Influence of immunosuppressive regimens. Liver Transpl 2001; 7: 1056.
37. Samonakis DN, Triantos C, Thalheimer U, et al. Immunosuppresion and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl 2005; 11: 386.
38. Cohen SM. Current immunosuppression in liver transplantation. American Journal of Therapeutics 2002; 9: 119.
39. Jain A, Kashyap R, Demetris AJ, et al. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 47.
40. Kronberg A, Kupper B, Tannapfel A, et al. Impact of mycophenolate mofetil versus azathioprine on early recurrence of hepatitis C after liver transplantation. Int Immunopharmacol 2005; 5: 107.
41. Zekry A, Gleeson M, Guney S, McCaughan GW. A prospective crossover study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004; 10: 52.
42. Bahra M, Neumann P, Jacob D, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course. Am J Transplant 2005; 5: 406.
43. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85.
44. Romero F, Rodriguez-Iturbe B, Parra G, et al. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 1999; 55: 945.
45. Roos N, Poulalhon N, Farge D, et al. In vitro evidence for a direct anti-fibrotic role of the immunosuppressive drug mycophenolate mofetil. J Pharmacol Exp Ther 2007; 321: 583.
46. Ventura CG, Coimbra TM, de Campos SB, et al. Mycophenolate mofetil attenuates renal ischemia/reperfusion injury. J Am Soc Nephrol 2002; 13: 1524.
47. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology 1997; 26: 459.
48. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929.
49. Manns MP, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. J Hepatol 1999; 31: 39.
50. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J Hepatol 1996; 24: 52.
51. Mukherjee S, Lyden E. Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: An open-label series. Liver Int 2006; 26: 529.
52. Abdelmalek MF, Firpi RJ, Soldevilla-Pico C, et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199.
53. Kimball P, Stravitz T. DR antigens influence graft outcome and HCV recurrence after liver transplantation. Transplant Proc 2005; 37: 1099.
54. Kirk AD, Heisey DM, D'Alessandro AM, et al. Clinical hepatitis after transplantation of hepatitis C virus-positive kidneys: HLA-DR3 as a risk factor for the development of posttransplant hepatitis. Transplantation 1996; 62: 1758.
55. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51: 248.
56. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004; 77: 84.
57. Alonso O, Loinaz C, Moreno E, et al. Advanced donor age increases the risk of severe recurrent hepatitis C after liver transplantation. Transpl Int 2005; 18: 902.
58. Jain A, Orloff M, Abt P, et al. Transplantation of liver grafts from older donors: Impact on recipients with hepatitis C virus infection. Transplant Proc 2005; 37: 3162.